Clinical trials: Complication in Systemic Lupus Erythematosus
Lupus Erythematosus, Systemic
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
This is a Phase 1b/2, single-arm, open-label, multi-center, clinical study of AZD0120, a CD19/BCMA dual CAR T cell therapy, to evaluate the safety, tolerability, and efficacy in adult participants with refractory Systemic Lupus…
- Trial name
- NCT06897930
- Testing
- AZD0120, Cyclophosphamide, Fludarabine
- Where
- 20 sites in United States, Australia and 2 more
- Volunteers
- 150 people
- Sponsor
- AstraZeneca
Vitamin D Deficiency, Hypocalcemia
Effect of Vitamin D Supplement on Disease Activity in SLE
To study the effect of vitamin D supplementation on disease activity of SLE ( SLEDAI-2K ) and IL-6 level
- Conditions
- Vitamin D Deficiency, Hypocalcemia, Hyperparathyroidism, Systemic Lupus Erythematosus (Disorder)
- Trial name
- NCT05260255
- Testing
- vitamin D2 ( calciferol )
- Where
- Thailand
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Department of Medical Services Ministry of Public Health of Thailand
Lupus Nephritis, Type 1 Diabetes Mellitus
Autologous Adoptive T Regulatory Cell Transfer in Autoimmune Diseases.
Investigators aim to develop an effective and safe treatment of autoimmune diseases through adoptive T regulatory cells transfer.
- Trial name
- NCT05566977
- Testing
- autologous adoptive T regulatory cell transfer.
- Where
- Egypt
- Volunteers
- 20 people
- Sponsor
- Ain Shams University
Lupus Nephritis
A Pilot Study for the Efficacy and Safety of Tacrolimus in the Treatment of Refractory Lupus Nephritis
The purpose of this protocol is to determine whether Tacrolimus and Prednisolone are effective and safe in the treatment of the cyclophosphamide-resistant, refractory diffuse proliferative lupus nephritis
- Trial name
- NCT00569101
- Testing
- tacrolimus
- Where
- South Korea
- Volunteers
- 9 people
- Sponsor
- Seoul National University Hospital
Lupus Nephritis
Concentration-controlled Therapy of Mycophenolate Mofetil (MMF) in Proliferative Lupus Nephritis
To evaluate therapeutic response to MMF treatment in patients with International Society of Nephrology/Renal Pathology Society (ISN/RPS) class III or IV lupus nephritis.
- Trial name
- NCT01042457
- Testing
- Mycophenolate mofetil
- Where
- Thailand
- Volunteers
- 24 people
- Sponsor
- Chulalongkorn University
Lupus Nephritis
Mycophenolic Acid Pharmacokinetics and Pharmacogenomics in Lupus Nephritis
This study investigate mycophenic acid (MPA) pharmacokinetics and pharmacogenomics and their impact on the clinical outcomes in lupus nephritis (LN) patients. Lupus nephritis patients (both active or inactive) will be recruited.
- Trial name
- NCT02453997
- Where
- 2 sites in Hong Kong
- Volunteers
- 88 people
- Sponsor
- The University of Hong Kong
Lupus Nephritis (LN), Chronic Kidney Disease
Dapagliflozin to Reduce the Decline in Renal Function in Patients Newly Diagnosed With Lupus Nephritis
Lupus nephritis is one of the most serious complications of lupus, an autoimmune disease in which the immune system mistakenly attacks the body's own tissues.
- Conditions
- Lupus Nephritis (LN), Chronic Kidney Disease, SGLT 2 Inhibitors, Systemic Lupus Erythematosus
- Trial name
- DAPA-LN (NCT07678203)
- Testing
- Dapagliflozin (10Mg Tab) along with standard medical therapy, Proteinuria Quantification
- Where
- Mexico
- Volunteers
- 30 people
- Sponsor
- Hospital Civil Juan I. Menchaca
Lupus Nephritis, Lupus Nephritis (LN)
Study to Evaluate the Safety and Preliminary Efficacy of CD19 CAR-T Cell Therapy (TranspoCART19) in Patients With Refractory Lupus Nephritis
The goal of this clinical trial is to evaluate the safety and preliminary efficacy of CD19 CAR-T cell therapy (TranspoCART19) in adults with refractory lupus nephritis.
- Trial name
- CART-NEL (NCT07799116)
- Testing
- TranspoCART19
- Where
- 8 sites in Spain
- Volunteers
- 10 people
- Sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Lupus Nephritis (LN)
Study to Assess Efficacy and Safety of HSK39297 Tablets in Patients With LN
A double-blind,placebo controlled,randomized Phase 2 study to evaluate the safety and tolerability of once-daily, oral administration of 200 or 300 mg HSK39297 tablets versus placebo in Patients With Lupus Nephritis
- Trial name
- NCT07363460
- Testing
- HSK39297 200mgQD, HSK39297 300mgQD
- Where
- China
- Volunteers
- 105 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Lupus Nephritis
Zanubrutinib in Participants With Active Proliferative Lupus Nephritis
The primary objective of this study is to evaluate the efficacy of zanubrutinib added to standard of care as measured by complete renal response for participants with active proliferative lupus nephritis
- Trial name
- NCT04643470
- Testing
- Zanubrutinib
- Where
- 44 sites in China
- Volunteers
- 177 people
- Sponsor
- BeiGene
Lupus Nephritis
Disease Activity Biomarkers in Patients With Systemic Lupus Erythematosus
The aim of this research project is to better understand the origin and clinical significance of two lupus-specific "genetic signatures" (IFN signature and plasma cell signature) in patient subgroups with well-defined clinical…
- Trial name
- JD001 (NCT05443516)
- Where
- Belgium
- Volunteers
- 250 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Lupus Nephritis
Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)
The purpose of this up to 6-year extension study is the evaluation of the efficacy and safety 1. after study treatment withdrawal in patients with lupus nephritis (LN) who achieved response (complete renal response [CRR] or…
- Trial name
- SIRIUS-LN ext (NCT06711887)
- Testing
- Ianalumab
- Where
- 51 sites in United States, Brazil and 16 more
- Volunteers
- 348 people
- Sponsor
- Novartis Pharmaceuticals
Lupus Nephritis, Autoimmune Diseases
A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease
ADI-202300103 is a phase 1 multicenter, open label, dose finding and dose expansion, safety/efficacy study in patients with autoimmune disease.
- Conditions
- Lupus Nephritis, Autoimmune Diseases, Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE)
- Trial name
- NCT06375993
- Testing
- ADI-001, Fludarabine, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 180 people
- Sponsor
- Adicet Therapeutics
Lupus Nephritis (LN)
Dapagliflozin in Active Lupus Nephritis
Lupus nephritis is a chronic and life-threatening autoimmune cause of kidney disease that predominately impacts young people and can lead to kidney failure.
- Trial name
- Dapa-Active LN (NCT07323524)
- Testing
- Dapagliflozin (10Mg Tab) along with standard medical therapy
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- Brigham and Women's Hospital
Antiphospholipid (aPL)-Positive, Rheumatic Arthritis
MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT)
The primary objective of this multicenter observational registry is to characterize the clinical, epidemiological, and biological profiles of individuals of Middle Eastern, North African, and Levantine ancestry, including…
- Conditions
- Antiphospholipid (aPL)-Positive, Rheumatic Arthritis, Celiac Disease, Focal Segmental Glomerulosclerosis (FSGS)
- Trial name
- MERIT (NCT07892651)
- Where
- Jordan
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Axiom Bioregistry
To Compare the Effects of Mycophenolate Mofetil With Cyclophosphamide in Neplaese Lupus Nephritis Patients
Cyclophosphamide Versus Mycophenolate Mofetil in Lupus Nephritis
This was a prospective open label randomized control trial, which was conducted for a period of one and half year from January 2014 to June 2015.
- Trial name
- NCT03200002
- Testing
- Cyclophosphamide, Mycophenolate Mofetil
- Volunteers
- 49 people
- Sponsor
- Chitwan Medical College
Lupus Nephritis
Open Label Pilot Trial of Rituximab in Lupus Membranous Nephritis
The objective of this study is to assess the as efficacy of rituximab as induction therapy in membranous lupus nephritis. Safety and tolerability will additionally be assessed.
- Trial name
- NCT00908986
- Testing
- Rituximab
- Sponsor
- Northwell Health
Systemic Lupus Erythematosus (SLE)
A Study of LCAR-AIO in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus
This is a prospective, single-arm, open-label, dose-exploration and expansion clinical study of LCAR-AIO in adult subjects with relapsed/refractory systemic lupus erythematosus.
- Trial name
- NCT06653556
- Testing
- LCAR-AIO T cells
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lupus Nephritis
Efficacy and Safety of Artesunate Plus Standard of Care in Active Lupus Nephritis
This is a multi-center, randomized, double-blind, placebo-controlled study. Study subjects are class III, IV, V, III+V, IV+V lupus nephritis patients, according to ISN/RPS 2003 classification of LN, with active lesion needing…
- Trial name
- AURORA (NCT03214731)
- Testing
- Artesunate
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Sun Yat-sen University
Lupus Nephritis
Epidemiology of Lupus Nephritis in Nephrology Unit in Assiut University Hospital
study epidemiology of lupus nephritis patients admitted to nephrology unit inward or in outpatient clinic in Assiut Nephrology Unit
- Trial name
- NCT05120882
- Volunteers
- 60 people
- Sponsor
- Assiut University